Trans-autophosphorylation of EGFRvIII mutant dimers

Stable Identifier
R-HSA-1248655
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Upon dimerization, EGFRvIII mutants trans-autophosphorylate on tyrosine residues Y992, Y1068, Y0186, Y1143 and Y1173 while the tyrosine residue Y1045, a docking site for CBL, remains either unphosphorylated or hypophosphorylated, allowing EGFRvIII to activate downstream signaling cascades while escaping downregulation.

Literature References
PubMed ID Title Journal Year
17646646 Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

Huang, PH, Mukasa, A, Bonavia, R, Flynn, RA, Brewer, ZE, Cavenee, WK, Furnari, FB, White, FM

Proc Natl Acad Sci U S A 2007
16969069 Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII

Han, W, Zhang, T, Yu, H, Foulke, JG, Tang, CK

Cancer Biol Ther 2006
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
protein tyrosine kinase activity of EGFRvIII mutant dimer [plasma membrane]
Physical Entity
Activity
Normal reaction
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!